Kirsten Elin Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kirsten Elin Smith has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
David H. Epstein
Real-World Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse, Intramural Research Program
21 shared publicationsChristopher R. McCurdy
13 shared publications- Oliver Grundmann
Department of Medicinal Chemistry, College of Pharmacy, University of Florida
12 shared publications Kelly E. Dunn
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
10 shared publicationsOliver Grundmann
College of Pharmacy, Department of Medicinal Chemistry, University of Florida, Gainesville, FL, USA
10 shared publicationsLeigh V. Panlilio
Real-World Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse, Intramural Research Program
9 shared publications
Latest Publications
- 20 December 2025
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 61 (8) , 1178-1184
Kratom ( Mitragyna speciosa ) as a Replacement for Alcohol Among a Sample of Malaysian Adults with a History of Alcohol Use Problems
Kratom (Mitragyna speciosa) is traditionally used for its medicinal value in Southeast Asia. While kratom is used as a substitute for narcotics, its utility remains unstudied among alcohol users. We determined the context and motives of kratom use in a sample who have used kratom to manage their alcohol use problem. Sixteen respondents who claimed to have used kratom to self-treat their alcohol use problem were recruited for this qualitative study. All the in-depth interviews were thematically analyzed. All males, and their mean age was 58.6 years (SD = 6.67). Kratom was ingested as a substitute for alcohol and to self-treat alcohol use problem. Kratom was shown to have the potential to reduce alcohol dependence, since there was a pronounced reduction in the frequency and intake (quantity) of alcohol use. Cessation from alcohol use occurred relatively fast, since respondents took about 1 to 3 months to abstain from it completely. No one has relapsed to alcohol use since initiating kratom. Despite having used kratom regularly, none stated to have developed dependence on it. While alcohol affected social functioning, conversely, kratom did not do so. Our findings highlight that kratom was being consumed as a substitute for alcohol and suggests its potential utility to reduce or cease alcohol consumption. However, further longitudinal studies are needed to confirm this finding.
- 20 December 2025
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 61 (8) , 1178-1184
Kratom ( Mitragyna speciosa ) as a Replacement for Alcohol Among a Sample of Malaysian Adults with a History of Alcohol Use Problems
Kratom (Mitragyna speciosa) is traditionally used for its medicinal value in Southeast Asia. While kratom is used as a substitute for narcotics, its utility remains unstudied among alcohol users. We determined the context and motives of kratom use in a sample who have used kratom to manage their alcohol use problem. Sixteen respondents who claimed to have used kratom to self-treat their alcohol use problem were recruited for this qualitative study. All the in-depth interviews were thematically analyzed. All males, and their mean age was 58.6 years (SD = 6.67). Kratom was ingested as a substitute for alcohol and to self-treat alcohol use problem. Kratom was shown to have the potential to reduce alcohol dependence, since there was a pronounced reduction in the frequency and intake (quantity) of alcohol use. Cessation from alcohol use occurred relatively fast, since respondents took about 1 to 3 months to abstain from it completely. No one has relapsed to alcohol use since initiating kratom. Despite having used kratom regularly, none stated to have developed dependence on it. While alcohol affected social functioning, conversely, kratom did not do so. Our findings highlight that kratom was being consumed as a substitute for alcohol and suggests its potential utility to reduce or cease alcohol consumption. However, further longitudinal studies are needed to confirm this finding.
- 5 November 2025
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 20 (6) , e258-e261
Substance Use Disorder Following Consumption of a Novel Synthetic 7-Hydroxymitragynine Product
Background: Products containing semi-synthetic 7-hydroxymitragynine (7-OH), a potent mu-opioid receptor (MOR) agonist, have proliferated in the United States. In kratom leaf, trace amounts of 7-OH are formed by spontaneous oxidization of kratom’s primary alkaloid, mitragynine. Hepatic and intestinal microsomes also convert mitragynine to 7-OH. Some products have sublingual and nasal administration routes that circumvent hepatic first-pass metabolism, increasing bioavailability and accelerating effect onset, features that increase risk. We report a patient who developed substance use disorder (SUD) related to a 7-OH sublingual film. Case Presentation: A 35-year-old man with supraventricular tachycardia and profound urinary retention described using “Hydroxie,” a novel, semi-synthetic 7-OH product. He currently vaped cannabis and nicotine, and reported injection heroin addiction a decade prior. He used kratom 6 months before trying Hydroxie, which began 10 weeks before hospitalization. Within days of initiating use, he noticed tolerance; within 2 weeks, he was using one film every 1–2 hours. The patient met criteria for severe SUD related to Hydroxie and was inducted onto buprenorphine. Analysis confirmed 7-OH in the product and blood. Discussion: The MOR selectivity and brief duration of action of some 7-OH formulations support our observation that repeated use may lead to physical dependence. Standard laboratory testing can detect mitragynine but not 7-OH due to its relatively shorter half-life, an issue that may confuse semi-synthetic 7-OH use with kratom. Novel 7-OH products are not kratom. The potency of 7-OH places unwitting consumers who may believe they are using kratom, not a partial MOR agonist, at risk.
- 5 November 2025
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 20 (6) , e258-e261
Substance Use Disorder Following Consumption of a Novel Synthetic 7-Hydroxymitragynine Product
Background: Products containing semi-synthetic 7-hydroxymitragynine (7-OH), a potent mu-opioid receptor (MOR) agonist, have proliferated in the United States. In kratom leaf, trace amounts of 7-OH are formed by spontaneous oxidization of kratom’s primary alkaloid, mitragynine. Hepatic and intestinal microsomes also convert mitragynine to 7-OH. Some products have sublingual and nasal administration routes that circumvent hepatic first-pass metabolism, increasing bioavailability and accelerating effect onset, features that increase risk. We report a patient who developed substance use disorder (SUD) related to a 7-OH sublingual film. Case Presentation: A 35-year-old man with supraventricular tachycardia and profound urinary retention described using “Hydroxie,” a novel, semi-synthetic 7-OH product. He currently vaped cannabis and nicotine, and reported injection heroin addiction a decade prior. He used kratom 6 months before trying Hydroxie, which began 10 weeks before hospitalization. Within days of initiating use, he noticed tolerance; within 2 weeks, he was using one film every 1–2 hours. The patient met criteria for severe SUD related to Hydroxie and was inducted onto buprenorphine. Analysis confirmed 7-OH in the product and blood. Discussion: The MOR selectivity and brief duration of action of some 7-OH formulations support our observation that repeated use may lead to physical dependence. Standard laboratory testing can detect mitragynine but not 7-OH due to its relatively shorter half-life, an issue that may confuse semi-synthetic 7-OH use with kratom. Novel 7-OH products are not kratom. The potency of 7-OH places unwitting consumers who may believe they are using kratom, not a partial MOR agonist, at risk.
- 31 October 2025
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 20 (6) , e253-e257
Complicating Factors Surrounding Concurrent Use of Kratom and a Novel 7-hydroxymitragynine Product Among a Participant Enrolled in a Kratom Clinical Trial
Background: 7-Hydroxymitragynine (7-OH) is a highly selective mu opioid receptor agonist with binding affinity greater than morphine. Although trace amounts of 7-OH are found in kratom, it is formed by metabolism in humans after kratom ingestion. Novel semi-synthetic 7-OH products are manufactured by mono-oxidation of kratom’s primary alkaloid, mitragynine. Formulations include sublingual tablets, powders, and liquid shots. We report a case of a study participant with self-reported 7-OH use. Case Presentation: A 23-year-old man using kratom for 3 years was enrolled into a clinical trial evaluating kratom pharmacokinetics, behavioral pharmacology, and withdrawal. He typically used 1.5-2g of kratom whole-leaf powder 6 times/day. Following scheduled kratom product self-administration during the study, several outcomes were atypical, including blunted subjective kratom effects. He reported recent initiation of a “new kratom product” (“Opia”) identified as semi-synthetic 7-OH; he was using 20 mg 3 times/day for 4 days before study admission. Mitragynine (29.7 ng/mL) plasma concentration peaked at 1.5 hours post kratom self-administration, while 7-OH C max (11.7 ng/mL) occurred before self-administration, confirming prior ingestion of 7-OH. The participant reported withdrawal symptoms and requested early discharge from the study, but refused the study protocol kratom “rescue dose,” stating he preferred to take his “stronger” product. Discussion: Clinicians must obtain detailed self-reports from patients who report any kratom use. As 7-OH products are misleadingly marketed as kratom, and as both long-time kratom consumers and kratom-naive individuals may experiment with these novel products, improved assessment methods are urgently needed in the absence of real-time confirmatory testing.
- 31 October 2025
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 20 (6) , e253-e257
Complicating Factors Surrounding Concurrent Use of Kratom and a Novel 7-hydroxymitragynine Product Among a Participant Enrolled in a Kratom Clinical Trial
Background: 7-Hydroxymitragynine (7-OH) is a highly selective mu opioid receptor agonist with binding affinity greater than morphine. Although trace amounts of 7-OH are found in kratom, it is formed by metabolism in humans after kratom ingestion. Novel semi-synthetic 7-OH products are manufactured by mono-oxidation of kratom’s primary alkaloid, mitragynine. Formulations include sublingual tablets, powders, and liquid shots. We report a case of a study participant with self-reported 7-OH use. Case Presentation: A 23-year-old man using kratom for 3 years was enrolled into a clinical trial evaluating kratom pharmacokinetics, behavioral pharmacology, and withdrawal. He typically used 1.5-2g of kratom whole-leaf powder 6 times/day. Following scheduled kratom product self-administration during the study, several outcomes were atypical, including blunted subjective kratom effects. He reported recent initiation of a “new kratom product” (“Opia”) identified as semi-synthetic 7-OH; he was using 20 mg 3 times/day for 4 days before study admission. Mitragynine (29.7 ng/mL) plasma concentration peaked at 1.5 hours post kratom self-administration, while 7-OH C max (11.7 ng/mL) occurred before self-administration, confirming prior ingestion of 7-OH. The participant reported withdrawal symptoms and requested early discharge from the study, but refused the study protocol kratom “rescue dose,” stating he preferred to take his “stronger” product. Discussion: Clinicians must obtain detailed self-reports from patients who report any kratom use. As 7-OH products are misleadingly marketed as kratom, and as both long-time kratom consumers and kratom-naive individuals may experiment with these novel products, improved assessment methods are urgently needed in the absence of real-time confirmatory testing.
- Open Access
- 25 October 2025
- Published by Elsevier in Addictive Behaviors Reports
- Vol. 22, 100638
Association of behavioral economic demand for kratom with DSM-5 use disorder: quantity and likelihood-based demand approaches
- 25 October 2025
- Published by Elsevier in Addictive Behaviors Reports
- Vol. 22, 100638
Open AccessAssociation of behavioral economic demand for kratom with DSM-5 use disorder: quantity and likelihood-based demand approaches
- 1 October 2025
- Published by American Psychological Association (APA) in Experimental and Clinical Psychopharmacology
- Vol. 33 (5) , 513-522
Is bedtime use of kratom (Mitragyna speciosa) a sleep aid or disruptor? Examining its daily effects and individual differences.
Kratom (Mitragyna speciosa) is a psychoactive botanical native to Southeast Asia increasingly used in the United States for various self-reported benefits, including sleep improvement. However, empirical evidence concerning kratom's effects on sleep is limited. Here, we examined the association between bedtime kratom use and self-reported sleep outcomes in naturalistic settings across consecutive days, while also exploring sex and chronic pain status as potential moderators. A secondary analysis was conducted using the data from a 15-day ecological momentary assessment study of 357 U.S. adults who reported regularly using kratom. Participants made daily reports of their bedtime kratom use and rated their sleep duration and quality. Linear mixed-effects models assessed associations between bedtime kratom use and sleep outcomes, with sex and chronic pain status as moderators, controlling for age. Bedtime kratom use occurred on 23.4% of days and was associated with modest increases in sleep duration (13 min) and perceived quality (5.93-point increase on a 0-100 scale). Female respondents reported greater improvements in sleep quality (but not duration) than male respondents. Participants with chronic pain reported greater improvements in sleep duration and quality compared to those without chronic pain. Bedtime kratom use is associated with modest sleep duration and quality improvements, particularly in adults with chronic pain, and better sleep quality in female respondents. These findings among experienced kratom consumers suggest the need for human laboratory studies in kratom-naïve participants to determine causality and underlying mechanisms, which could help inform clinical guidance and policy as kratom use continues to rise. (PsycInfo Database Record (c) 2025 APA, all rights reserved).
- 1 October 2025
- Published by American Psychological Association (APA) in Experimental and Clinical Psychopharmacology
- Vol. 33 (5) , 513-522
Is bedtime use of kratom (Mitragyna speciosa) a sleep aid or disruptor? Examining its daily effects and individual differences.
Kratom (Mitragyna speciosa) is a psychoactive botanical native to Southeast Asia increasingly used in the United States for various self-reported benefits, including sleep improvement. However, empirical evidence concerning kratom's effects on sleep is limited. Here, we examined the association between bedtime kratom use and self-reported sleep outcomes in naturalistic settings across consecutive days, while also exploring sex and chronic pain status as potential moderators. A secondary analysis was conducted using the data from a 15-day ecological momentary assessment study of 357 U.S. adults who reported regularly using kratom. Participants made daily reports of their bedtime kratom use and rated their sleep duration and quality. Linear mixed-effects models assessed associations between bedtime kratom use and sleep outcomes, with sex and chronic pain status as moderators, controlling for age. Bedtime kratom use occurred on 23.4% of days and was associated with modest increases in sleep duration (13 min) and perceived quality (5.93-point increase on a 0-100 scale). Female respondents reported greater improvements in sleep quality (but not duration) than male respondents. Participants with chronic pain reported greater improvements in sleep duration and quality compared to those without chronic pain. Bedtime kratom use is associated with modest sleep duration and quality improvements, particularly in adults with chronic pain, and better sleep quality in female respondents. These findings among experienced kratom consumers suggest the need for human laboratory studies in kratom-naïve participants to determine causality and underlying mechanisms, which could help inform clinical guidance and policy as kratom use continues to rise. (PsycInfo Database Record (c) 2025 APA, all rights reserved).
- 25 August 2025
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 61 (2) , 237-246
Diversification of Kratom in US Markets: Results from an Online Survey and Chemical Assay of Products
Kratom (Mitragyna speciosa) products in the US have diversified from dried leaf to now include edibles, extracts, teas, and tonics. Higher alkaloid content and/or greater oral exposure across formulations expose consumers to potentially greater amounts of alkaloids per serving in a shorter duration of time, thereby potentially increasing product effect and risk profiles. Six kratom vendors disseminated our anonymous online survey. Participants reported on products use patterns, perceived benefits, and adverse effects. Product samples were classified: powders, edibles, liquids, and teas and were analyzed for alkaloid content using UPLC-MS/MS. The final sample consisted of 421 participants, using 61 products. They were 61.8% male and 46.3% between 31 and 50 years. Whole-leaf powders were most popular and reported to provide more pain relief, energy, and improved sleep compared to other products. The most common adverse effect was constipation (73.4%). Edibles were associated with tolerance while liquids were associated with consuming more than intended. Alkaloid content was significantly higher in edibles and whole-leaf powders compared to teas and concentrated liquid extracts. Diversification of kratom products and higher alkaloid content per serving or dose expose consumers to inadvertent toxicity. Further clinical investigation of risk profiles for different formulations is needed.
- 25 August 2025
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 61 (2) , 237-246
Diversification of Kratom in US Markets: Results from an Online Survey and Chemical Assay of Products
Kratom (Mitragyna speciosa) products in the US have diversified from dried leaf to now include edibles, extracts, teas, and tonics. Higher alkaloid content and/or greater oral exposure across formulations expose consumers to potentially greater amounts of alkaloids per serving in a shorter duration of time, thereby potentially increasing product effect and risk profiles. Six kratom vendors disseminated our anonymous online survey. Participants reported on products use patterns, perceived benefits, and adverse effects. Product samples were classified: powders, edibles, liquids, and teas and were analyzed for alkaloid content using UPLC-MS/MS. The final sample consisted of 421 participants, using 61 products. They were 61.8% male and 46.3% between 31 and 50 years. Whole-leaf powders were most popular and reported to provide more pain relief, energy, and improved sleep compared to other products. The most common adverse effect was constipation (73.4%). Edibles were associated with tolerance while liquids were associated with consuming more than intended. Alkaloid content was significantly higher in edibles and whole-leaf powders compared to teas and concentrated liquid extracts. Diversification of kratom products and higher alkaloid content per serving or dose expose consumers to inadvertent toxicity. Further clinical investigation of risk profiles for different formulations is needed.
- Open Access
- 15 July 2025
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 16, 100361
Kratom use among ethnobotanical tea bar patrons in Colorado: Subjective drug effects, adverse reactions, and perceived benefits of use
- 15 July 2025
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 16, 100361
Open AccessKratom use among ethnobotanical tea bar patrons in Colorado: Subjective drug effects, adverse reactions, and perceived benefits of use
- Top Cited Papers
- 8 May 2025
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 272, 112701
De facto opioids: Characterization of novel 7-hydroxymitragynine and mitragynine pseudoindoxyl product marketing
- 8 May 2025
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 272, 112701
Top Cited PapersDe facto opioids: Characterization of novel 7-hydroxymitragynine and mitragynine pseudoindoxyl product marketing
- 22 March 2025
- Published by Springer Nature in Current Addiction Reports
- Vol. 12 (1) , 1-11
Systematic Review of Clinical Case Reports Involving Tianeptine Products: “Gas Station Heroin” Hype or Fact?
- 22 March 2025
- Published by Springer Nature in Current Addiction Reports
- Vol. 12 (1) , 1-11
Systematic Review of Clinical Case Reports Involving Tianeptine Products: “Gas Station Heroin” Hype or Fact?
- Open Access
- 30 January 2025
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 51 (2) , 191-203
At least four groups of kratom consumers in the United States: latent-class analysis of motivations for kratom use
Background: Kratom is a plant with alkaloids acting at opioid, serotonergic, adrenergic, and other receptors. Consumers report numerous use motivations.Objectives: To distinguish subgroups of kratom consumers by kratom-use motivations using latent-class analysis.Methods: From July to November 2022, we utilized convenience sampling and surveyed regular kratom consumers (n = 395, 38.1 years (SD 11.2), 54.9% male, 81.3% White) regarding demographics, lifetime and past-year substance use and preferences, substance use disorder history, healthcare barriers, kratom-use motivations, and general health. We used latent-class analysis to identify subgroups by use motivation and calculated conditional probabilities (Pc) for variables in each class.Results: A four-class model best fit our data. The largest class (32.4%) was characterized by the use of kratom for self-treatment of chronic pain (Pc = .91). The smallest class (19.2%) also reported using kratom for self-treatment, but usually as a long-term replacement for other substances (Pc = .75). The other two classes (24.8% and 23.5%) reported using kratom for management of anxiety (Pc = .87-.95) and depressive symptoms (Pc = .61-.89) and for recreation (Pc = .56- .86). These were distinguished from one another by probability of at least moderate kratom use disorder (Pc = .17 vs. .53), with greater probability observed in the class with greater anxiety (Pc = .13 vs. .50) and depressive (Pc = .34 vs. .82) symptom severity and more likely recreational use motivation (Pc = .56 vs. .86).Conclusion: Kratom consumers can be classified by their use motivations. As with other psychoactive substances, the range of motivations is consistent with the range of likely effects. It is not yet clear whether some motivations might indicate the risk of problems.
- 30 January 2025
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 51 (2) , 191-203
Open AccessAt least four groups of kratom consumers in the United States: latent-class analysis of motivations for kratom use
Background: Kratom is a plant with alkaloids acting at opioid, serotonergic, adrenergic, and other receptors. Consumers report numerous use motivations.Objectives: To distinguish subgroups of kratom consumers by kratom-use motivations using latent-class analysis.Methods: From July to November 2022, we utilized convenience sampling and surveyed regular kratom consumers (n = 395, 38.1 years (SD 11.2), 54.9% male, 81.3% White) regarding demographics, lifetime and past-year substance use and preferences, substance use disorder history, healthcare barriers, kratom-use motivations, and general health. We used latent-class analysis to identify subgroups by use motivation and calculated conditional probabilities (Pc) for variables in each class.Results: A four-class model best fit our data. The largest class (32.4%) was characterized by the use of kratom for self-treatment of chronic pain (Pc = .91). The smallest class (19.2%) also reported using kratom for self-treatment, but usually as a long-term replacement for other substances (Pc = .75). The other two classes (24.8% and 23.5%) reported using kratom for management of anxiety (Pc = .87-.95) and depressive symptoms (Pc = .61-.89) and for recreation (Pc = .56- .86). These were distinguished from one another by probability of at least moderate kratom use disorder (Pc = .17 vs. .53), with greater probability observed in the class with greater anxiety (Pc = .13 vs. .50) and depressive (Pc = .34 vs. .82) symptom severity and more likely recreational use motivation (Pc = .56 vs. .86).Conclusion: Kratom consumers can be classified by their use motivations. As with other psychoactive substances, the range of motivations is consistent with the range of likely effects. It is not yet clear whether some motivations might indicate the risk of problems.